HC Wainwright & Co. Initiates Coverage On Reneo Pharmaceuticals with Buy Rating, Announces Price Target of $30
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Gobind Singh initiates coverage on Reneo Pharmaceuticals with a Buy rating and announces a price target of $30.
August 28, 2023 | 10:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Reneo Pharmaceuticals receives a Buy rating from HC Wainwright & Co. with a price target of $30.
The Buy rating and price target of $30 announced by HC Wainwright & Co. for Reneo Pharmaceuticals indicates a positive outlook for the company's stock. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100